Sanofi's venglustat bombs again, but isn't dead yet

Shortly after failing a Parkinson's disease study, Sanofi's venglustat has missed the mark in another trial in autosomal dominant polycystic kidney disease (ADPKD), whittling down the list

Scotland backs NHS use of Alexion's Ultomiris for rare disea...

NHS patients in Scotland with the rare disease atypical haemolytic uremic syndrome (aHUS) will now be able to access treatment with Alexion's Ultomiris, ahead of their counterparts in Engla

AstraZeneca's Farxiga claims first SGLT2 kidney disease OK f...

AstraZeneca is already seeing sales rocket for its SGLT2 inhibitor Farxiga in heart failure, and is expected to gather even more momentum after claiming FDA approval in chronic kidney disea

FDA sets September review date for Calliditas' rare kidney d...

Calliditas Therapeutics could have its first product on the market in the US this autumn, as the FDA has now started a priority review of Nefecon for rare disease primary IgA nephropathy (I

Calliditas eyes 2022 approval in EU for rare kidney disease ...

Calliditas Therapeutics is on course to launch its first product, Nefecon for rare disease primary IgA nephropathy (IgAN), in the first half of 2022 after getting the green light for an acc

Alnylam files its third RNAi drug lumasiran in rare kidney d...